Stocks · News reference
Rhythm Pharmaceuticals Announces Preliminary Results From Ongoing Phase 2 Trial Evaluating RM-718 In Patients With Acquired Hypothalamic Obesity; BMI Reductions Consistent With Setmelanotide And Bivamelagon; Sees -11.6% Mean Reduction In BMI From Baseline At Week
Eleven patients with acquired HO were enrolled in the ongoing, open-label trial. Key preliminary findings include:-11.6% reduction in mean BMI from baseline (n=7) after 16 weeks of RM-718;RM-718 efficacy results at 16
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 10:57 AM
- Checked
- Aug 4, 2026, 10:57 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesity in adults and children 4 and older.
Read original at benzingaRhythm Pharmaceuticals Says UK MHRA Expands IMCIVREE Marketing Authorization To Acquired Hypothalamic Obesity In Patients 4 And Older, Grants Orphan Drug Designation
Read original at benzingaJP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.
Read original at benzinga